Technology

The Cern Device

Designed to be a safe, effective prescription device/gel treatment delivering controlled, visible-spectrum microbicidal light for localized management of recurrent yeast and bacterial vaginal infections — intended for use at home, as needed, when needed, based on familiar, recurring symptoms.
  • A reusable, precision-engineered intravaginal light-emitting device
  • A proprietary, natural photosensitizing lubricant that enhances microbicidal activity
  • A prescriptive treatment which is designed for home use
Device and gel depicted are for illustrative purposes only and may not represent the final commercial product.

A precision-engineered,
three-part system.

The Cern treatment combines a reusable light-emitting device, a proprietary photosensitizing gel, and a prescriptive protocol designed for home use.
01 — The Device

Light-Emitting Device

A reusable, precision-engineered intravaginal device that emits controlled, visible-spectrum microbicidal light.

02 — The Gel

Photosensitizing Lubricant

A proprietary, naturally derived photosensitizing lubricant that enhances microbicidal activity and reduces treatment duration.
03 — The Protocol

Designed for Home Use

A prescriptive treatment designed for home use — applied similarly to a tampon, as needed, when needed.
Proprietary Gel

The photosensitizing gel that powers the light.

The gel contains a proprietary, naturally derived photosensitizer and functions as a lubricant to facilitate device insertion and improve treatment delivery. It enhances the efficiency of the light-based treatment, helping to reduce required treatment duration.

The gel does not possess independent antimicrobial activity and is not intended to alter or disrupt the vaginal microbiome. The antimicrobial effect is driven entirely by the device’s controlled, low-level, visible-spectrum light activated locally at the site of infection.

Dual-Pathogen Focus

One device. Two of the most common
vaginal infections.

The CernDevice™ is being developed to address vulvovaginal candidiasis (yeast) and bacterial vaginosis (BV)—two common conditions that frequently coexist but are typically treated separately with antifungal and antibiotic drugs. Cern’s localized, device-based therapy is uniquely positioned to address both fungal and bacterial pathogens through a single treatment modality, offering a differentiated, non-drug approach for women experiencing yeast and/or bacterial infections, including those that may be recurrent.

Yeast (Candida)

Recurrent vulvovaginal candidiasis, including drug-resistant Candida strains conventional antifungals struggle to treat.

Bacterial Vaginosis

Recurrent BV — with broader reproductive- health implications, including increased preterm birth risk.